MMI-0100 产品活性：MMI-0100 是一种细胞渗透性肽抑制剂，抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程，例如静脉移植疾病。 产品来源： https://www.medchemexpress.cn/mmi-0100.html 研究领域：MAPK/ERK Pathway 作用靶点：MAPKAPK2 (MK2) In Vitro: Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. . MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone. MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100. MMI-0100 does not induce EC apoptosis at any dose. In Vivo: MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model. 相关产品：Clinical Compound Library Plus | Bioactive Compound Library Plus | Peptide Library | Zunsemetinib | Gamcemetinib | MK2-IN-1 hydrochloride | PF-3644022 | MK2-IN-3 | Tpl2 Kinase Inhibitor 1 | CMPD1 | Norartocarpetin | DB1113 | MK2-IN-5 acetate | MK2-IN-4 | Peraquinsin | Quazinone | RMM-46 | SMU-L11 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。